Rankings
▼
Calendar
SUPN Q3 2019 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
SUPN
Supernus Pharmaceuticals, Inc.
$3B
Q3 2019 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$102M
-0.8% YoY
Gross Profit
$97M
95.3% margin
Operating Income
$40M
38.9% margin
Net Income
$29M
28.3% margin
EPS (Diluted)
$0.54
QoQ Revenue Growth
-2.4%
Cash Flow
Operating Cash Flow
$38M
Free Cash Flow
$37M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$1.1B
Total Liabilities
$550M
Stockholders' Equity
$557M
Cash & Equivalents
$117M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$102M
$103M
-0.8%
Gross Profit
$97M
$99M
-1.5%
Operating Income
$40M
$37M
+6.0%
Net Income
$29M
$28M
+3.0%
Revenue Segments
Product
$100M
98%
Royalty
$2M
2%
← FY 2019
All Quarters
Q4 2019 →